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Abstract
Background: Increasing incidence and lack of survival improvement in adolescents and young adults (AYAs) with
cancer have led to increased awareness of the cancer burden in this population. The objective of this study was to
describe overall and type-specific cancer incidence and mortality trends among AYAs in Western Australia from
1982–2007.
Methods: Age–adjusted incidence and mortality rates were calculated for all malignancies combined and for each
of the most common diagnostic groups, using five-year age–specific rates. Joinpoint regression analysis was used to
derive annual percentage changes (APC) for incidence and mortality rates.
Results: The annual incidence rate for all cancers combined increased in males from 1982 until 2000 (APC = 1.5%,
95%CI: 0.9%; 2.1%) and then plateaued, whilst rates for females remained stable across the study period
(APC =−0.1%; 95%CI: −0.2%; 0.4%) across the study period. For males, significant incidence rate increases were
observed for germ cell tumors, lymphoblastic leukemia and thyroid cancer. In females, the incidence of Hodgkin’s
lymphoma, colorectal and breast cancers increased. Significant incidence rate reductions were noted for cervical,
central nervous system and lung cancers. Mortality rates for all cancers combined decreased from 1982 to 2005 for
both males (APC =−2.6%, 95%CI:−3.3%;−2.0%) and females (APC =−4.6%, 95%CI:−5.1%;−4.1%). With the exception of
bone sarcoma and lung cancer in females, mortality rates for specific cancer types decreased significantly for both
sexes during the study period.
Conclusions: Incidence of certain AYA cancers increased, whilst it decreased for others. Mortality rates decreased
for most cancers, with the largest improvement observed for breast carcinomas. Further research is needed to
identify the reasons for the increasing incidence of certain cancers.
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Background
Cancers in adolescents and young adults (AYAs), aged
15–39 years, account for less than 10% of all new cancer
diagnoses in developed countries [1]. The most com-
monly occurring malignancies in this age group differ
markedly from those in older adults and younger chil-
dren [2,3]. In children (<15 years), embryonal tumors
represent the most prevalent neoplasms, whereas the
most common cancers in older adults (>39 years) are
epithelial malignancies of the lung, prostate, breast and
colorectum [2]. In AYAs, nearly all invasive cancers are
accounted for by lymphomas, leukemias, germ cell
tumors, melanoma and carcinomas [4,5].
Recent major advances in treatment and coordinated
international research efforts have led to remarkable
improvements in childhood cancer outcomes. However,
AYAs, while having a higher and increasing incidence of
cancer, have not benefited from similar improvements.
During the past years, this deficit has become the subject
of international focus and initiatives [2,6] but in Australia,
few empirical reports have specifically focused on cancer
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outcomes among AYAs. Herein, we provide data on recent
cancer incidence and mortality rates, and a detailed ana-
lysis of long–term trends for the most prevalent malignan-
cies among AYAs, using routinely-collected administrative
health data in Western Australia (WA) during the period
1982–2007.
Methods
A retrospective cohort study of AYA cancer incidence and
mortality trend was conducted using whole-population,
health record linkage in WA. Incident cases included all
malignant neoplasms registered from January 1, 1982 to
December 31, 2007. Patient death date used to calculate
mortality trend was restricted to December 31, 2005.
Cases were restricted to those in individuals aged 15–39
years at diagnosis. Notifications of all malignancies, in-
cluding in situ and malignant neoplasms and excluding
non-melanoma skin cancer, have been a statutory require-
ment since 1981 in WA. Cancer registrations include in-
formation on basic demographic data (date of birth, sex,
Aboriginality, area of residence) and tumor data (date of
diagnosis, tumor site, morphology, behaviour, grade, basis
of diagnosis, information on subsequent primary malig-
nancies) and vital status. Active data follow-up of all
patients was performed by the WA Data Linkage Service
(WADLS) through linkage of the Cancer Registry, the
Mortality Register, and the Hospital Morbidity Data Sys-
tem, which contains information on all hospital separations
within WA. Anonymised linked records from the Cancer
Registry, the Mortality Register, and the Hospital Morbidity
Data System (containing information on all hospital
separations within WA) were provided by the WADLS.
Malignancies were classified according to histological ori-
gin as described in the 3rd edition of the International
Classification of Diseases for Oncology and further grouped
according to the most prevalent cancer types based on the
Surveillance, Epidemiology, and End Results Program
(SEER) AYA cancer diagnostic groups (Table 1). The
groups were based on the AYA classification scheme which
was developed to better define the major cancer sites that
affect individuals between 15 and 39 years of age [7].
Data analysis
Five-year age−adjusted incidence and mortality rates
were calculated by sex and SEER AYA diagnostics
groups. Rates were adjusted by direct standardization
against the five−year age distribution of the standard
Australian population in 2001. Annual population esti-
mates used in the calculation of the rates were obtained
from the Australian Bureau of Statistics. Analyses were
performed for all malignancies combined and for diag-
nostic groups and subtypes separately. Joinpoint regres-
sion analysis was used to identify points at which
statistically significant changes in temporal trend
occurred. The annual percentage change (APC) in each
joinpoint segment is the rate of change in a cancer rate
per year in a given time frame. Changes in rates included
a shift in the magnitude or a change in the direction of
the rate. A negative APC indicates a decreasing trend
whereas a positive APC indicates an increasing trend.
Joinpoint analyses were performed using the Joinpoint
Regression Program (3.4) [8]. Subtypes of certain diag-
nostic groups were excluded from joinpoint regressions
because there were too few cases to allow for a trend
analysis. Incidence and mortality rates and standard
errors were calculated using SAS 9.2.
Ethics approval for this study was obtained from the
University of Western Australia Research Ethics Com-
mittees (reference number: RA/4/1/2228).
Results
There were 12238 incident cases of malignant neoplasms
reported from 1982–2007, among AYAs aged 15–39 years.
Table 1 Number of cases, sex ratio, and International
Classification of Diseases for Oncology topography and
histology codes
Diagnostic Group n (%) M:F
Leukaemia 444 (3.6) 1.4
ALL 120 (1.0) 1.7
AML & CML 276 (2.3) 1.2
Other 48 (0.4) 2.5
Lymphoma 907 (7.4) 1.3
NHL 472 (3.9) 1.6
HL 435 (3.5) 1.0
CNS Tumour 406 (3.3) 1.3
Bone 183 (1.5) 1.4
Soft Tissue 323 (2.6) 1.4
Germ Cell 960 (7.8) 10.5
Gonadal 875 (7.1) 24.0
Non−gonadal 85 (0.7) 1.4
Melanoma 3551 (29.0) 0.9
Carcinoma 5012 (40.9) 0.4
Thyroid 640 (5.2) 0.3
Lip & oral cavity 515 (4.2) 3.6
Gonads 107 (0.9) 0.01
Lung 129 (1.1) 1.1
Breast 1440 (11.8) na
Cervix 782 (6.4) na
Colorectum 500 (4.1) 1.0
Other 899 (7.3) 2.2
Other 452 (3.7) 0.6
Total 12238 0.7
CNS central nervous system; ALL acute lymphocytic leukaemia; AML and CML
acute and chronic myeloid leukaemia;
HD Hodgkin’s disease; NHL Non−Hodgkin’s lymphoma; M:F: Sex ratio, na not
applicable.
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Table 1 presents the histological distribution of the
tumours. Detailed data on the AYA classification groups
and histological codes are provided as Additional file 1:
Table S1.
All malignancies combined
Trends in age−adjusted rates and the results of the join-
point analysis for all malignancies combined and for the
individual cancer types are shown in Figures 1, 2, 3 and 4
and Tables 2 & 3. The overall incidence of malignancies
in males significantly increased between 1982 and 2000
(APC= 1.5%), after which there was no significant change
in the rates. In contrast, incidence rates for females
remained stable throughout the study period. Mortality
significantly decreased, during the study period, for both
males (APC=−2.6%) and females (APC=−4.6%).
Leukemias and lymphomas
The incidence of acute lymphoblastic leukaemia (ALL)
increased significantly among males (APC= 3.6%), and
Figure 1 Trends in age−adjusted incidence for all malignancies combined and selected diagnostic groups for adolescents and young
adults of ages 15–39 years, 1982–2007 a. a dots represent observed rates and solid lines represent the (LOWESS) smoothed trend.
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that of Hodgkin’s lymphoma (HL) increased (APC=
2.6%) among females. No evidence of change in inci-
dence was observed for other haematological cancers.
A significant downward trend in myeloid leukaemia mor-
tality was evident (males, APC=−5.6%; females, APC=
−5.0%). A significant downward trend in Non-Hodgkin
Lymphoma (NHL) mortality was also observed among
both males (APC=−4.8%) and females (APC=−4.5%).
CNS, bone and soft tissue sarcomas & germ cell tumors
For all CNS tumours combined a modest (but statisti-
cally significant) decrease in incidence rates was
observed in males (APC=−1.2%) with no trend evident
among females. Male germ cell tumours, comprising
predominately (approximately 94%) gonadal tumors,
also increased (APC= 2.6%). No changes in the inci-
dence of bone tumours or soft tissue tumours in either
sex, or of female germ cell tumours were evident, al-
though this is likely due to the smaller number of
cases.
A significant decline in mortality from CNS tumours
was observed from 1982-2005 for males (APC=−3.1%)
and between 1982 and 2005 for females (APC=−4.6%).
Soft tissue sarcoma mortality decreased among females
Figure 2 Trends in age−adjusted incidence for all malignancies combined and selected diagnostic groups for adolescents and young
adults of ages of 15–39 years, 1982–2007.
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(APC=−3.7%). No evidence of change in mortality from
soft tissues sarcoma was observed for the males.
Melanoma and carcinomas
Incidence of melanoma significantly increased from 1982
until 1999 for males (APC= 3.5%) and until 2000 for
females (APC= 1.6%). Afterwards, the incidence of mel-
anoma declined significantly for both males (APC=
−5.3%) and females (APC=−3.8%). A small but signifi-
cant increase in incidence was observed for breast car-
cinomas (APC= 0.5%). Cervical carcinoma incidence
(APC=−2.7%) also decreased significantly. Thyroid
carcinoma incidence increased significantly for both
sexes (males, APC= 4.0%; females, APC= 2.1%). Inci-
dence rates increased significantly for colorectal carcin-
oma (APC= 1.4%) among females only and lung
carcinoma incidence significantly decreased for males
only (APC=−2.6%).
Melanoma mortality decreased from 1982-2005 for
both sexes (male, APC=−5.5%; females, APC=−10.9%).
Mortality rates for all carcinomas combined decreased
for males (APC=−2.4%). In females, incidence (−3.0%)
was similar to males from 1982− 96 but a steeper decline
in mortality was observed thereafter (APC=−8.2%). This
Figure 3 Trends in age−adjusted mortality for all malignancies combined and selected diagnostic groups for adolescents and young
adults of ages 15–39 years, 1982–2005.
Haggar et al. BMC Cancer 2012, 12:151 Page 5 of 10
http://www.biomedcentral.com/1471-2407/12/151
trend was likely driven by breast cancer mortality, which
significantly decreased from 1982–1996 (APC=−2.9%)
and was followed by another more rapid significant de-
crease thereafter (APC=−14.4%). Mortality from ovarian
cancer (APC=−2.6%) and cervical cancer (APC=−6.8%)
cancer decreased significantly. Significant reductions in
mortality rates were observed for colorectal carcinoma in
both males (APC=−2.1%) and females (APC=−2.3%).
Lung carcinoma mortality significantly decreased for
males only (APC=−2.8%).
Discussion
Improvements in modern treatments and diagnosis has
led to reductions in incidence and mortality attributed to
many neoplasms, including those that commonly occur
among AYAs [5]. However, incidence is still increasing
for some cancers that commonly occur among AYAs
and decline in mortality has lagged for certain cancers.
This is the first study to have comprehensively
investigated cancer incidence and mortality trends at the
whole population level for a broad range of cancers that
commonly occur among Australian AYAs aged 15–39
years using the adolescent and young classification
scheme.
Increases in incidence rates were observed for testicu-
lar cancer, thyroid cancer, and ALL among male AYAs,
whereas in young females, the incidence of HL, breast,
and colorectal cancers increased over the 26-year study
period. Decreases in the incidence of lung cancer and
CNS tumors were observed among males only, cervical
cancer among females, and melanoma for both the sexes.
Between 1982-2005, cancer mortality rates decreased for
both sexes, although considerable disparity existed be-
tween males and females by cancer type.
Despite expanding knowledge on many AYAs cancers,
the reasons for the increasing incidence of some cancers
are still poorly understood, particularly for testicular can-
cer [9]. Known risks factors for testicular cancer include
Figure 4 Trends in age−adjusted mortality for all malignancies combined and selected diagnostic groups for adolescents and young
adults of ages 15–39 years, 1982–2005.
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cryptorchidism, testicular atrophy and maternal expo-
sures [10,11]. Exposure to ionizing radiation, particularly
in childhood, may influence the incidence of thyroid car-
cinoma later in life [12]. However, the sex differential
observed among AYAs in this study is not clear, although
it may imply a specific susceptibility gene hormone re-
ceptor in the pathogenesis of thyroid carcinomas or pos-
sibly due to a greater medical surveillance in young
women. Some of the increase in the incidence of thyroid
cancer may be also explained by the use of improved
diagnostic tests, although diagnostic scrutiny alone is un-
likely to explain the trends observed in this study. De-
creasing exposures to infections in childhood and
thereby increased susceptibility later in life may play a
role in the occurrence of both ALL and HL in adoles-
cence and young adults. In fact, Epstein Barr virus, in
particular, may play a role in the incidence of a substan-
tial proportion of HL cases [13].
There was a small but significant increase in breast
cancer incidence. This may be a result of recent
improvements in diagnostic imaging of the dense
fibroglandular breast in young women and adjuvant
chemotherapy and radiation therapy. Other potential
contributing factors may include use of oral contracep-
tives and changes in the fertility patterns [14]. Fortu-
nately, breast cancer mortality among young WA
women decreased over the same period. In fact, this
group experienced the greatest decrease in mortality in
this study, particularly post 1996. This is likely due
advances in newer imaging techniques, such as magnetic
resonance imaging (MRI), that can detect tumors previ-
ously occult because of the dense fibroglandular breast
in young women. The recent reduction in the financial
barrier through a Medicare rebate for MRI fee for young
women <50 years of age and at high risk of breast can-
cer has the potential to further decrease mortality in this
population.
The overwhelming majority of lung cancers in AYAs
are caused by tobacco smoking. Tobacco control is cur-
rently a priority in Australia, with WA seen as the na-
tional leader in this area [15]. Smoking prevention and
cessation programs are aimed not only at the general
Table 2 Joinpoint analysis of age−adjusted incidence rates per 100 000, AYAs aged 15–39 years in Western Australia,
1982–2007
Incidence rates, Males Incidence rates , Females
Trend 1 Trend 2 Trend 1 Trend 2
Diagnostic Groups Period APC 95% CI c Period APC 95% CI Period APC 95% CI Period APC 95% CI
All Tumours 82− 00 1.5* ( 0.9; 2.1) 00− 07 −1.4*(-3.4;0.7) 82− 07 −0.1* (-0.2; 0.4)
Leukaemia 82− 07 0.8 *(-0.7; 2.4) 82− 07 0.0* (-2.1; 2.1)
Myeloid 82− 07 −0.3* (-2.1; 1.6) 82− 07 −0.4* (-2.6; 2.0)
Lymphocytic 82− 07 3.6* ( 0.1; 7.2) 82− 07 −1.5* (-4.5; 1.6)
Lymphoma 82− 07 0.0* (-1.2; 1.3) 82− 07 1.4* (-0.3; 3.1)
NHL 82− 07 0.9* (-0.6; 2.4) 82− 07 0.5* (-1.5; 2.5)
HL 82− 07 −1.5* (-3.3; 0.3) 82− 07 2.6* ( 0.6; 4.7)
CNS 82− 07 −1.2* (-2.3; 0.1) 82− 07 −1.2* (-3.2; 0.8)
Bone Tumor 82− 07 −0.1* (-2.0; 1.9) 82− 07 0.0* (-2.7; 2.8)
Soft Tissue 82− 07 −1.2* (-2.9; 0.4) 82− 07 0.8* (-1.1; 2.7)
Germ Cell 82− 07 2.6* ( 1.6; 3.6) 82− 07 0.1* (-2.7; 3.0)
Gonadal 82− 07 2.6* ( 1.8; 3.9) 82− 07 −0.1* (-3.6; 3.4)
Non-gonadal 82− 07 −0.6* (-3.7; 2.5) 82− 07 0.2* (-3.6; 4.2)
Melanoma 82− 00 3.5* ( 2.3; 4.6) 00− 07 −5.3*(-9.1;-1.4) 82− 99 1.6* ( 0.0; 3.1) 99− 07 −3.8*(-7.7; 0.3)
Carcinoma 82− 07 1.0* ( 0.4; 1.5) 82− 07 0.3* (-0.1; 0.7)
Breast na na 82− 07 0.5* ( 0.0; 0.9)
Colon & Rectum 82− 07 −0.4* (-1.7; 1.0) 82− 07 1.4* ( 0.1; 2.7)
Ovary na na 82− 07 −0.3* (-2.3; 1.9)
Lung 82− 07 −2.6* (-4.3;-0.9) 82− 07 0.4* (-1.3; 2.0)
Cervix Uteri na na 82− 07 −2.7* (-3.5;-1.8)
Thyroid 82− 07 4.0* ( 2.0; 6.1) 82− 00 2.1* ( 0.9; 3.2) 00− 07 13.8*(-0.6;30.3)
Lip & Oral Cavity 82− 07 0.6* (-0.7; 2.0) 82− 07 1.1* (-1.1;-3.3)
* The annual percentage change (APC) is statistically significantly different from 0 (p< 0.05).
a Effective sample size less than 10.
c95% CI, 95% confidence interval.
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population, but are increasingly targeting young people.
However, while there has been some recent evidence of a
decreasing trend in both incidence and mortality among
men [16], the situation in women, particularly young
women, is a cause for concern. The present study results
indicate that young women are not experiencing the
same decline in lung cancer incidence as young men,
which is consistent with known disparity of historical
smoking uptake and cessation trends between genders
[17,18]. Nonetheless, it is expected that recent declines
in female smoking rates would eventually result in a de-
cline in the future incidence and mortality for AYA
females [19].
Colorectal cancer is uncommon among younger AYAs
but rises substantially after the age of 25 years [20]. The
incidence of colorectal cancer increased for young
females in our study, but not in males. Yet, hereditary
predisposition, the main risk factor in this age group is
expected to be similar in both sexes [21]. Sex hormones
have immuno-modulatory effects and may differentially
affect the incidence of colorectal cancer in AYAs [22-24].
However, the observed trend in incidence among females
in our study is more likely to be attributed to environ-
mental factors, such as changes in nutrition, smoking
and alcohol consumption [21], although these factors
could not be evaluated in our study [21]. Overall, mortal-
ity due to colorectal cancer has decreased substantially
in the last decades. Recognition of familial colorectal
cancer syndromes and refinement of diagnostic techni-
ques are likely to have contributed to reductions in mor-
tality among AYAs.
Trends in incidence and mortality of both cervical can-
cer and melanoma are largely influenced by earlier can-
cer detection and improved treatments. Cervical cancer
screening to detect potentially pre-cancerous changes
which are usually caused by sexually transmitted human
papillomaviruses (HPV) infection is likely responsible for
the decreases in incidence and deaths observed in our
study. The recent implementation of the HPV
immunization program in Australia, in 2007, is likely to
further reduce the burden of cervical cancer. In WA, the
spread of independent skin cancer clinics might have ini-
tially increased the incidence of cutaneous melanomas as
result of increased detection of indolent cases through
increased surveillance [25]. The rise seems to have
reversed more recently, possibly as a result of changes in
recreational behavior and increased protection from sun
exposure [26]. Continued skin awareness campaigns are
likely to further decrease incidence and mortality due to
melanomas.
Table 3 Joinpoint analysis of age-adjusted mortality rates per 100 000, AYAs aged 15–39 years in Western Australia,
1982–2005
Mortality rates, Males Mortality rates, Females
Trend 1 Trend 1 Trend 2
Diagnostic Groups Period APC 95% CI Period APC 95% CI Period APC 95% CI
All Tumours 82− 05 −2.6* (-3.3; -2.0) 82− 05 −4.6* (-5.1; -4.1)
Leukaemia 82− 05 −3.6* (-5.9; -1.2) 82− 05 −3.8* (-6.1; -1.5)
Myeloid 82− 05 −5.6* (-8.0; -3.1) 82− 05 −5.0* (-8.3; -1.6)
Lymphocytic 82− 05 1.6 (-1.5; 4.8) 82− 05 −2.2 (-5.3; -0.9)
Lymphoma a 82− 05 −5.4* (-7.4; -3.4) 82− 05 −4.9* (-7.7; -2.0)
NHL 82− 05 −4.8* (-7.1; -2.5) 82− 05 −4.5* (-7.3; -1.7)
CNS 82− 05 −3.1* (-4.8; -1.4) 82− 05 −4.6* (-6.9; -2.1)
Bone 82− 05 −1.8 (-5.0; 1.5) 82− 05 4.3* (-0.4; 9.2)
Soft Tissue 82− 05 −4.7* (-7.6; 1.8) 82− 05 −3.7* (-7.0; -0.2)
Germ Cell a 82− 05 −8.2* (-10.5;-5.8) 82− 05 −1.3 (-6.1; 3.6)
Gonadal 82− 05 −7.7* (-10.3;-5.1)
Melanoma 82− 05 −5.5* (-7.5; -3.4) 82− 05 −10.9* (-13.5;-8.2)
Carcinoma a 82− 05 −2.4* (-3.4; -1.5) 82− 96 −3.0* (-4.2; -1.7) 96− 05 −8.2* (-10.7; -5.5)
Breast na na 82− 96 −3.0* (-4.2; -1.3) 96− 05 −14.4* (-18.4; -9.9)
Colon & Rectum 82− 05 −2.1* (-4.0; -0.1) 82− 05 −2.3* (-3.7;-0.8)
Ovary na na 82− 05 −2.6 (-5.5; -0.5)
Lung 82− 05 −2.8* (-5.2; -0.3) 82− 05 −0.9* (-1.3; 3.1)
Cervix Uteri na na 82− 05 −6.8* (-8.2; -5.3)
Lip & Oral Cavity 82− 05 −3.4* (-5.5; -1.3)
* The annual percentage change (APC) is statistically significantly different from 0 (p< 0.05).
a Data for HL, non-gonadal germ cells and thyroid cancers and lip/oral in females were not reported due to low effective sample size less than 95% CI, 95%
confidence interval.
Haggar et al. BMC Cancer 2012, 12:151 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/151
The overall pattern of increasing incidence [27-30] and
decreasing mortality [31,32] of AYA cancers reported in
this study approximates that observed in other developed
countries, including in the United States, Canada and
some western European nations. Increasing incidence of
specific cancers such as thyroid [33-35], testicular [36,37]
observed in this study population appears to be consist-
ent with results from other AYA populations. The emer-
ging lung cancer epidemic observed among females in
our study is also consistent with other studies from sev-
eral developed countries [38-41]. Cervical cancer inci-
dence and mortality rates continued to decrease among
AYAs in WA and other developed countries [42,43], al-
though declines seem to be moderating or plateauing in
some populations [44,45].
A strength of this study is its use of routinely-collected,
whole-population data from the WADLS, which has
undergone extensive validation with false-positives and
false-negatives shown to be <1% [46]. Using these data,
we investigated incidence and mortality trends over a
26-year period for AYAs aged between 15-39 years, and
this is the first comprehensive analysis of cancer inci-
dence and mortality trends among for a broad range of
cancers that commonly occur among AYAs in Australia.
Although WA’s population of 2.3 million is not very
large, WA population is representative of the rest of Aus-
tralia; it is closest to the average of the eight Australian
states and territories with respect to: median age; distribu-
tion of sex, people living in remote areas, income, per
capita health expenditure and hospital bed supply. In
addition, the relatively low and stable overseas and internal
migration (~2%) of the WA population has the advantage
of reduced loss to follow-up. These characteristics of WA
and the completeness of our data strengthened our study.
However, a number of challenges exist, particularly in
the interpretation of results for rare cancers. Random
fluctuations may erroneously appear as noteworthy
trends and, therefore, care must be exercised in inter-
preting the trends for these cancers. Multiple compari-
sons were adjusted to ensure an overall type I error rate
of 0.05 through the joinpoint permutation test. However,
spurious associations are still possible due to the large
number of statistical tests conducted. Important sub-
population trends may have been obscured, given the
epidemiological heterogeneity of the study population,
particularly its broad age range and ethnic diversity, and
the potential for interaction of these with both the
spectrum of cancers identified and health service utilisa-
tion. In addition, AYA cancers represent a heterogeneous
group of diseases with specific etiologies. Nonetheless,
the observed differences in the trends between the sexes
and across cancer subgroups provide starting points for
etiologic research. Testable hypotheses, including indi-
vidual characteristics and environmental exposures, can
be investigated in relation to specific cancers through
further rigorous study designs.
Conclusion
We have presented data representing a comprehensive
longitudinal analysis of cancer incidence and mortality
among AYAs in WA. Mortality from cancer showed per-
sistent downward trends between 3% and 5% among
young men and women in the last ten years of the study.
We observed favourable trends in mortality, particularly
among AYAs diagnosed with testicular cancer, HL, leu-
kaemias and other neoplasms amenable to treatment.
This might also reflect major trends in the risk factors
and preventive interventions. Notwithstanding these
major improvements, incidence continues to rise for cer-
tain cancer types such as ALL, HL, and breast, colorec-
tal, testicular and thyroid cancers. Thus, further research
into the aetiology of the distinctive spectrum of cancers
affecting AYAs and more widespread adoption of screen-
ing, early diagnosis should become key priorities for can-
cer control among AYAs.
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